Evidence Hub

The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients

Younsoo Chung, S. Jeong, Sang-Hun Song, S. K. Hong

Investigative and Clinical Urology, 2026

57 participants · 1 citation

Abstract

Purpose This study evaluated the clinical impact of escalating tamsulosin dosage from 0.2 to 0.4 mg in men with benign prostatic hyperplasia (BPH) who exhibited inadequate responses to the lower dose. Materials and Methods A retrospective review was performed on 57 patients treated at Seoul National University Bundang Hospital in 2022. Uroflowmetry parameters, International Prostate Symptom Score (IPSS), and postvoid residual volume (PVR) were compared before and after dose escalation. Subgroup analysis was conducted by age, prostate volume, and concomitant 5-alpha-reductase inhibitor use. Results The mean maximum urinary flow rate value improved significantly from 14.4 to 17.7 mL/s (p50 mL. Conclusions Escalating tamsulosin from 0.2 to 0.4 mg can meaningfully improve urinary flow in certain BPH patients, particularly those with larger prostates or concomitant 5-alpha-reductase inhibitor therapy.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free